drugset / Trial / NCT00648141

Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis

NCT00648141

Phase 3 Completed 458 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis

Timeline

Start
2003-01
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral
Comparator Diclofenac Other / unclassified 75 mg Oral